Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Publikováno v:
The Oncologist
Trial Information Click here to access other published clinical trials. Lessons Learned Studies targeting cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin (C-CAG) regimen in relapsed and refra
Autor:
Janet R. Vos, Sera Langenveld, Liesbeth Spruijt, Ingrid E Fakkert, Edward M Leter, Marjolijn J. L. Ligtenberg, Arjen R. Mensenkamp, Riki W. Willems, Nicoline Hoogerbrugge, Iris D. Nagtegaal
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 147, 2150-2158
International Journal of Cancer, 147, 8, pp. 2150-2158
International Journal of Cancer, 147(8), 2150-2158. Wiley
International Journal of Cancer, 147, 2150-2158
International Journal of Cancer, 147, 8, pp. 2150-2158
International Journal of Cancer, 147(8), 2150-2158. Wiley
Universal mismatch repair deficiency (dMMR) testing of colorectal cancer (CRC) is promoted as routine diagnostics to prescreen for Lynch syndrome. We evaluated the yield and experience of age‐related molecular investigation for heritable and nonher
Autor:
Pradip Devhare, Rajan Datar, Sewanti Limaye, Madhavi Apastamb, Ajay Srinivasan, S. Pawar, Tim Crook, Pooja Fulmali, Shoeb Patel, Sanket Patil, Cynthe Sims, Vineet Datta, Raymond L. Page, Archana Adhav, Navin Srivastava, Sachin Apurwa, Anantbhushan Ranade, Pradeep Fulmali, Dadasaheb Akolkar, Rohit Chougule, Akshay Ainwale, Revati Patil, Darshana Patil
Publikováno v:
International Journal of Cancer
Circulating ensembles of tumor‐associated cells (C‐ETACs) which comprise tumor emboli, immune cells and fibroblasts pose well‐recognized risks of thrombosis and aggressive metastasis. However, the detection, prevalence and characterization of C
Autor:
Hiten Naik, Susie Su, Doris Howell, Tristan A. Barnes, Mindy Liang, Nicole Mittmann, Wei Xu, Zachary William Neil Veitch, Hamzeh Albaba, Lawson Eng, Sharara Shakik, Andrea Perez-Cosio, Tian Wang, Geoffrey Liu, M. Catherine Brown
Publikováno v:
The Oncologist
regorafenib dosing in patients with metastatic or recurrent gastrointestinal stromal tumors after failure of imatinib and sunitinib.
Background. Recent studies have demonstrated improved outcomes with real‐time patient‐reported outcome quest
Background. Recent studies have demonstrated improved outcomes with real‐time patient‐reported outcome quest
Autor:
Kotaro Ozasa, Mai Utada, Alina V. Brenner, Munechika Misumi, Dale L. Preston, Ritsu Sakata, Kiyohiko Mabuchi, Atsuko Sadakane, Hiromi Sugiyama, Eric J. Grant
Publikováno v:
International Journal of Cancer
Radiation effects on colorectal cancer rates, adjusted for smoking, alcohol intake and frequency of meat consumption and body mass index (BMI) by anatomical subsite (proximal colon, distal colon and rectum) were examined in a cohort of 105,444 atomic
Autor:
Gideon M. Blumenthal, Haiyan Chen, Nicholas C. Richardson, Yvette L. Kasamon, Jingjing Ye, Ann T. Farrell, Richard Pazdur, R. Angelo de Claro
Publikováno v:
The Oncologist
This article summarizes the clinical review and basis of approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone as a first‐line regimen for patients with CD30‐expressing peripheral T‐cell lymphoma.
Publikováno v:
International Journal of Cancer
While overweight among adults has been linked with renal cell carcinoma (RCC) risk, little is known about the potential influence of overweight and obesity during adolescence. To ascertain if adolescent body mass index is associated with subsequent r
Autor:
Shubham Pant, Samuel McNeely, Ling Gao, Mansoor N. Saleh, Roberto Carlesi, Van K. Morris, C. Terret, Huzhang Mao, Philippe A. Cassier, Amanda Long, Siqing Fu, Lauriane Eberst, Gurudatta Naik, Erin K. Wagner
Publikováno v:
Oncologist
Trial Information Click here to access other published clinical trials. Lessons Learned The combination of the antivascular endothelial growth factor receptor 2 monoclonal antibody, ramucirumab, and the type II MET kinase inhibitor, merestinib, is to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6da28aca92f18edeb01b84065f999b
https://europepmc.org/articles/PMC7648328/
https://europepmc.org/articles/PMC7648328/
Autor:
Bassel F. El-Rayes, Walid L. Shaib, Madhusmita Behera, Olatunji B. Alese, Renjian Jiang, Mehmet Akce, Christina Wu
Publikováno v:
Oncologist
BACKGROUND. High‐grade neuroendocrine carcinomas are rare in the gastrointestinal tract. However, treatment patterns and outcomes have not been well described. SUBJECTS, MATERIALS, AND METHODS. The National Cancer Database was analyzed. The primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5650aaea4bf34b91157d460f6c5dca4
https://europepmc.org/articles/PMC7216443/
https://europepmc.org/articles/PMC7216443/
Autor:
Kirsten B. Goldberg, Richard Pazdur, Lei Nie, Jonathon Vallejo, Donna Przepiorka, E. Dianne Pulte, Ann T. Farrell, Amy E. McKee
Publikováno v:
The Oncologist
In 2017, the Food and Drug Administration granted accelerated approval of blinatumomab for the treatment of relapsed or refractory precursor B‐cell acute lymphoblastic leukemia. This article focuses on evidence to support conversion from accelerate